Therapeutic Effect of Recombinant Human Interleukin-11 on Thrombopenia in Children with Acute Non-Lymphocytic Leukemia after Chemotherapy

Objective To explore the preventive and therapeutic effect of recombinant human interleukin-11(rhIL-11) on thrombocytopenia in children with non-lymphocytic leukemia after chemotherapy.Methods Sixteen children who had non-lymphocytic leukemia were divided into 2 groups by randomization,including a therapeutic group and a control group.RhIL-11[50 μg/(kg·d)] was injected subcutaneously 24 h after chemiotherapy in the therapeutic group,and applied consecutively 10-14 days,and the control group was treated without RhIL-11.Duration of the thrombocytopenia,infusion of blood platelet,diversity of blood platelets counts and adverse effect were observed of the 2 groups.Differences between groups were examined using statistics analysis.Results There were 16 case-times(59.3%) in the therapeutic group that of could be cured without platelet transfusion,but that of control group only had 3 case-times(14.3%);the diffe-rence between 2 groups was significant(P0.01).The descending time of blood platelets counts in therapeutic group was significantly shorter than that in the control group,and the recovery of the therapeutic group was also significantly shorter than the control group(Pa0.01).The main adverse effect was debility,oedema,all of which could relieve.Conclusions rhIL-11 can accelerate the platelet recovery and reduce the need for platelet transfusion after consolidation chemotherapy in acute non-lymphocytic leukemia,and rhIL-11 plays an important role in the production which differention and maturation of megakaryocytes.rhIL-11 has significant preventive and therapeutic effect on non-lymphocytic leukemia after intense chemotherapy,with little adverse effect.rhIL-11 used with chemotherapy can reduce bleeding,and chemotherapy can proceed smoothly.